Comparative Evaluation of Sugammadex and Neostigmine for Reversal of Rocuronium-Induced Neuromuscular Block
International Journal of Pharmaceutical Quality Assurance · 09.07.2026 · 16 (10)
DOI: 10.25258/ijpqa.16.10.62 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 09.07.2026. Verfasst von Anil Kumar und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Rocuronium-induced neuromuscular blockade (NMB) is widely used in anesthesia but carries the risk of residual neuromuscular blockade (RNMB), leading to postoperative complications. Neostigmine is traditionally used for reversal but has delayed onset and muscarinic side effects. Sugammadex offers rapid and selective reversal of aminosteroid NMBAs.
Aim
To compare the efficacy and safety of sugammadex versus neostigmine for reversal of rocuronium-induced NMB. Methodology: In this prospective, randomized study, 80 adult patients undergoing elective surgery under general anesthesia were allocated to receive either sugammadex (2 mg/kg; n=40) or neostigmine with glycopyrrolate (0.05/0.01 mg/kg; n=40) for NMB reversal. Recovery times, extubation, post-anesthesia care unit (PACU) stay, and adverse events were recorded.
Results
Time to TOF ratio ≥0.9 was significantly faster with sugammadex (2.7 ± 0.9 min) than neostigmine (12.1 ± 3.0 min; p
Zitieren
APA
Kumar, A., Gupta, A., & Singh, A. K. (2026). Comparative Evaluation of Sugammadex and Neostigmine for Reversal of Rocuronium-Induced Neuromuscular Block. International Journal of Pharmaceutical Quality Assurance, 16(10). https://doi.org/10.25258/ijpqa.16.10.62
Vancouver
Kumar A, Gupta A, Singh AK. Comparative Evaluation of Sugammadex and Neostigmine for Reversal of Rocuronium-Induced Neuromuscular Block. International Journal of Pharmaceutical Quality Assurance. 2026;16(10). doi:10.25258/ijpqa.16.10.62
BibTeX
@article{Kumar2026,
author = {Kumar, Anil and Gupta, Anjali and Singh, Alok Kumar},
title = {Comparative Evaluation of Sugammadex and Neostigmine for Reversal of Rocuronium-Induced Neuromuscular Block},
journal = {International Journal of Pharmaceutical Quality Assurance},
year = {2026},
volume = {16},
number = {10},
doi = {10.25258/ijpqa.16.10.62}
}
EUVIMED